Literature DB >> 9409791

Bone formation with use of rhBMP-2 (recombinant human bone morphogenetic protein-2).

H D Zegzula1, D C Buck, J Brekke, J M Wozney, J O Hollinger.   

Abstract

We examined the effect of rhBMP-2 (recombinant human bone morphogenetic protein-2), delivered in a porous poly(DL-lactic acid) implant, on bone formation in a critical-sized defect in the radial diaphysis in rabbits. A unilateral segmental defect, twenty millimeters long, was created in the radius in ninety-six skeletally mature New Zealand White rabbits. Forty-eight rabbits were evaluated at four weeks and forty-eight, at eight weeks. Six groups were studied at each time-period. The defect was left empty in one group (control), the defect was filled with an autogenous corticocancellous bone graft in one group, and the defect was filled with a porous poly(DL-lactic acid) implant containing zero, seventeen, thirty-five, or seventy micrograms of rhBMP-2 (one group each). Radiographs of the defects were made every two weeks. The percentage of the total area of the defect that was radiopaque was determined with use of computerized radiomorphometry, and this percentage was used as a quantitative measure of the extent of new-bone formation in the defect. There were time and dose-dependent responses to rhBMP-2 for as long as four weeks; thereafter, the effects of seventeen, thirty-five, and seventy micrograms of rhBMP-2 were independent of dose and time (p < or = 0.05). The defects that had been treated with either thirty-five or seventy micrograms of rhBMP-2 had a significantly greater (p < or = 0.05) area of radiopacity than the defects that had been treated with either zero or seventeen micrograms of rhBMP-2. No significant difference could be found between the defects treated with thirty-five or seventy micrograms of rhBMP-2 and the defects filled with an autogenous graft. Healing and bone formation were examined histologically and histomorphometrically as well. At four weeks, polarized light microscopy revealed remnants of poly(DL-lactic acid) only in the defects that had been filled with an implant containing zero micrograms of rhBMP-2. At eight weeks, regardless of the dose of rhBMP-2, poly(DL-lactic acid) was not visible on histological examination. The presence of multinucleated giant cells was the hallmark of the inflammatory response elicited by poly(DL-lactic acid). At four and eight weeks, macrophages and lymphocytes were also present. The intensity of the cellular response at four weeks suggested an inverse relationship between these cells and the dose of rhBMP-2 -- that is, there appeared to be more multinucleated giant cells in defects treated with zero micrograms of rhBMP-2 than in defects treated with seventy micrograms of rhBMP-2. At eight weeks, multinucleated giant cells were rare in the defects treated with seventeen, thirty-five, or seventy micrograms of rhBMP-2. Histomorphometric data at four and eight weeks indicated that the amount of bone formation in the defects treated with seventeen, thirty-five, or seventy micrograms of rhBMP-2 was equivalent to the amount in the defects treated with an autogenous graft and was significantly less (p < or = 0.05) in the untreated defects and the defects treated with zero micrograms of rhBMP-2 (p < or = 0.05). By eight weeks, only thirty-five and seventy micrograms of rhBMP-2 had restored cortices and marrow elements.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9409791     DOI: 10.2106/00004623-199712000-00003

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  27 in total

1.  Dose-dependent effects of combined IGF-I and TGF-beta1 application in a sheep cervical spine fusion model.

Authors:  F Kandziora; R Pflugmacher; M Scholz; J Schäfer; G Schollmeier; G Schmidmaier; G Duda; M Raschke; N P Haas
Journal:  Eur Spine J       Date:  2002-11-08       Impact factor: 3.134

2.  Effect of recombinant human bone morphogenetic protein-2 on the osseointegration of dental implants: a biomechanics study.

Authors:  Nikitas Sykaras; Anthony M Iacopino; Robert G Triplett; Victoria A Marker
Journal:  Clin Oral Investig       Date:  2004-07-29       Impact factor: 3.573

3.  Osteogenic protein-1 delivered by hydroxyapatite-coated implants improves bone ingrowth in extracortical bone bridging.

Authors:  Neil Saran; Renwen Zhang; Robert E Turcotte
Journal:  Clin Orthop Relat Res       Date:  2010-09-28       Impact factor: 4.176

Review 4.  Cell-free and cell-based approaches for bone regeneration.

Authors:  Ericka M Bueno; Julie Glowacki
Journal:  Nat Rev Rheumatol       Date:  2009-11-10       Impact factor: 20.543

5.  Nano-fibrous tissue engineering scaffolds capable of growth factor delivery.

Authors:  Jiang Hu; Peter X Ma
Journal:  Pharm Res       Date:  2011-01-14       Impact factor: 4.200

6.  Long-term safety and efficacy of human bone morphogenetic protein (HBMP) in the treatment of resistant non-unions and failed arthrodesis.

Authors:  Arya Nick Shamie; Hamed Yazdanshenas; Eric Egan Johnson
Journal:  J Clin Orthop Trauma       Date:  2016-11-16

7.  Radiographic Assessment of Bone Formation Using rhBMP2 at Maxillary Periapical Surgical Defects: A Case Series.

Authors:  M Siva Kumar; M Hari Kumar; K Vishalakshi; H Sabitha
Journal:  J Clin Diagn Res       Date:  2016-04-01

8.  Delivery vehicle effects on bone regeneration and heterotopic ossification induced by high dose BMP-2.

Authors:  Laxminarayanan Krishnan; Lauren B Priddy; Camden Esancy; Brett S Klosterhoff; Hazel Y Stevens; Lisa Tran; Robert E Guldberg
Journal:  Acta Biomater       Date:  2016-12-08       Impact factor: 8.947

9.  Effect of chemotherapy on segmental bone healing enhanced by rhBMP-2.

Authors:  Jose A Morcuende; Pablo Gomez; Jeffrey Stack; George Oji; James Martin; Douglas C Fredericks; Joseph A Buckwalter
Journal:  Iowa Orthop J       Date:  2004

10.  Titanium implants and BMP-7 in bone: an experimental model in the rabbit.

Authors:  V Franke Stenport; C Johansson; S Joo Heo; P Aspenberg; T Albrektsson
Journal:  J Mater Sci Mater Med       Date:  2003-03       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.